Dose Reduction of EGFR‐TKIs for EGFR‐positive Non‐small Cell Lung Cancer: A Retrospective Study
Reducing TKI dose is an option for patients with <i>EGFR</i>-mutated NSCLC, especially in elderly or underweight patients who develop adverse effects, and there is no reason to hesitate to reduce the TKI dose in these patients.
Authors
- Toshihiro Shiozawa (ORCID: https://orcid.org/0000-0002-5869-8494)
- Shinya Sato (ORCID: https://orcid.org/0000-0001-6649-6975)
- Yohei Yatagai
- Yosuke Maezawa
- Gen Ohara
- Hiroaki Satoh (ORCID: https://orcid.org/0000-0002-1561-1723)
- Shinichiro Okauchi (ORCID: https://orcid.org/0000-0002-9262-0949)
- Hiroaki Matsumoto (ORCID: https://orcid.org/0000-0001-5096-1537)
- Takahide Kodama (ORCID: https://orcid.org/0000-0002-7029-1881)
- Kunihiko Miyazaki
- Akira Mochizuki
- Nobuyuki Hizawa
Institutions
- University of Tsukuba (JP)
- National Hospital Organization Mito Medical Center (JP)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2025-03-01
- DOI
- https://doi.org/10.21873/cdp.10431
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52